|
Monieziasis
|
C01.610.335.190.628 |
|
|
Ataxin-2
|
D12.776.157.725.452.125 |
|
|
Hepatolenticular Degeneration
|
C10.228.140.163.100.360 |
|
|
Genes, Bacterial
|
G05.360.340.358.207.249 |
|
|
Mali
|
Z01.058.290.190.500 |
|
|
Chromoblastomycosis
|
C17.800.838.208.241 |
|
|
Maximum Allowable Concentration
|
N06.850.460.350.210 |
|
|
Chemokine CCL18
|
D12.644.276.374.200.110.100 |
|
|
Methylenetetrahydrofolate Reductase (NADPH2)
|
D08.811.682.662.290 |
|
|
Contraindications, Drug
|
E02.208.200 |
|
|
Moclobemide
|
D02.455.426.559.389.127.250.875 |
|
|
GAP-43 Protein
|
D12.776.631.400 |
|
|
Tumor Stem Cell Assay
|
E05.200.500.388.930 |
|
|
Drug Screening Assays, Antitumor
|
E05.200.500.388 |
|
|
Diphosphoglyceric Acids
|
D02.705.400.140 |
|
|
Ethylamines
|
D02.092.471 |
|
|
Halobacteriales
|
B02.200.400 |
|
|
Activin Receptors, Type I
|
D08.811.913.696.620.682.700.062.500 |
|
|
Leprosy
|
C01.150.252.410.040.552.475.371 |
|
|
Panniculitis, Lupus Erythematosus
|
C17.800.566.400 |
|
